ESSA PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.72 USD | -1.72% |
|
-15.26% | -13.33% |
| May. 20 | Top Premarket Decliners | MT |
| May. 14 | ESSA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 349M 253M |
|---|---|---|---|---|---|
| Net income 2024 * | -46M -33.38M | Net income 2025 * | -72M -52.25M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-7.38
x | P/E ratio 2025 * |
-5.65
x | Employees | 50 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.73% |
More Fundamentals
* Assessed data
More news
Latest transcript on ESSA Pharma Inc.
More recommendations
More press releases
| 1 day | -1.72% | ||
| 1 week | -15.26% | ||
| Current month | -15.26% | ||
| 1 month | -8.48% | ||
| 3 months | -37.89% | ||
| 6 months | +4.76% | ||
| Current year | -13.33% |
1 week
5.53
6.01
1 month
5.526.85
Current year
5.5211.67
1 year
2.5811.67
3 years
1.4030.26
5 years
1.4036.00
10 years
1.40245.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Parkinson
CEO | Chief Executive Officer | 73 | 15-06-23 |
David Wood
DFI | Director of Finance/CFO | 66 | 13-09-30 |
Peter Virsik
COO | Chief Operating Officer | - | 16-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 15-03-04 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 19-07-30 |
Richard Glickman
CHM | Chairman | 65 | 10-09-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 5.72 | -1.72% | 47,885 |
| 24-06-06 | 5.82 | -0.85% | 26,852 |
| 24-06-05 | 5.87 | +1.73% | 19,794 |
| 24-06-04 | 5.77 | -3.35% | 54,166 |
| 24-06-03 | 5.97 | -11.56% | 84,739 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Calendar
2024-08-12
- Q3 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.867
CAD
Average target price
26.62
CAD
Spread / Average Target
+238.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.33% | 254M | |
| +51.85% | 57.87B | |
| +41.16% | 40.25B | |
| -5.25% | 39.94B | |
| -5.16% | 28.54B | |
| +12.79% | 26.4B | |
| -20.18% | 19.33B | |
| +30.88% | 12.4B | |
| +0.61% | 12.23B | |
| +25.06% | 12.2B |
- Stock Market
- Equities
- EPIX Stock
